Use of conventional antipsychotics and the cost of treating schizophrenia

Health Care Financing Review

Volumn 23, Issue 2, 2001, Pages 83-99

  Lyu, Ramon R ^a   McCombs, Jeffrey S ^a   Johnstone, Bryan M ^a   Muse, Donald N ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; CHLORPROMAZINE; DISULFIRAM; FLUPHENAZINE; HALOPERIDOL; HALOPERIDOL DECANOATE; HYPNOTIC SEDATIVE AGENT; LOXAPINE; MESORIDAZINE; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; PERPHENAZINE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

ADULT; AGED; ARTICLE; COST OF ILLNESS; DRUG COST; DRUG USE; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; SCHIZOPHRENIA; UNITED STATES;

ADULT; AGED; ALABAMA; ANTIPSYCHOTIC AGENTS; COST OF ILLNESS; DRUG COSTS; DRUG UTILIZATION REVIEW; FEMALE; GEORGIA; HEALTH CARE COSTS; HUMANS; KENTUCKY; MALE; MEDICAID; MICHIGAN; MIDDLE AGED; SCHIZOPHRENIA; UNITED STATES;

EID: 0035720985     PISSN: 01958631     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Practice guideline for the treatment of patients with schizophrenia
2. Treatment of schizophrenia: Let's talk dollars and sense
3. Variations in the use of medical and surgical services by the Medicare population
4. Information needs for medication coverage decisions in a state Medicaid program
5. Managing the care of schizophrenia: Lessons from a 4-year Massachusetts Medicaid study
6. Longitudinal course and outcome of schizophrenia
7. Pharmacoeconomics of schizophrenia in the 21st century
8. Medical comorbidity in schizophrenia
9. Health insurance status and service utilization in a community sample of persons with non-affective psychosis: The national comorbidity survey
10. Treatment of schizophrenia
11. Psychopharmacologic treatment of schizophrenia
12. Schizophrenic disorders
13. Expenditures for treating schizophrenia: A population-based study of Georgia Medicaid recipients
14. Use patterns for conventional antipsychotic medications in Medicaid patients with schizophrenia
15. Antipsychotic drug patterns and the cost of treating schizophrenia
16. The use of conventional antipsychotic medications for patients with schizophrenia in a Medicaid population: Therapeutic and cost outcomes over two years
17. A selective review of recent North American long-term follow-up studies of schizophrenia
18. The economic burden of schizophrenia: Conceptual and methodological issues, and cost estimates
19. The cost of schizophrenia: Assessing the burden
20. The development of the state mental hospital system in the United States
21. Economic evaluation in schizophrenia
22. Schizophrenia: An economic perspective